Autoimmune lymphoproliferative syndrome (ALPS) is caused by mutations of the genes encoding for Fas receptor (CD95), Fas ligand or other genes involved in apoptosis. [1] [2] [3] When Fas binds to Fas ligand, intracellular signal transduction and caspase activation lead to apoptosis, which is important for lymphocyte homoeostasis and immune tolerance by elimination of autoreactive cells. Failure of lymphocyte apoptosis leads to accumulation of autoreactive clones and lymphoproliferation. ALPS is a clinically and genetically heterogeneous disease.
The syndrome includes type 0, caused by homozygous Fas mutations with complete Fas deficiency and severe clinical features, type Ia with heterozygous Fas mutations, type Ib with heterozygous FAS-ligand mutations, type II with caspase-10 mutations and type III with no identifiable mutation. Fas mutations have variable penetrance, according to the mutated gene domain. 1 Clinical course is variable and includes lymphoproliferation with lymphadenopathy, splenomegaly or hepatomegaly and various autoimmune phenomena. 3, 4 Hypergammaglobulinaemia, autoantibodies and increased CD4 and CD8 double-negative T cells are typical. 1, 3 There is an increased risk for lymphoproliferative malignancies. 5 Various agents have been used for the treatment of autoimmune cytopenias, and experience with stem cell transplantation for the treatment of ALPS is very limited.
We report a 33-year-old man with ALPS and severe refractory ITP successfully treated with an HLA-identical sibling RIC stem cell transplantation (SCT) and subsequent DLI. He presented in early childhood with lymphadenopathy, neutropenia and hypergammaglobulinaemia. Subsequent clinical problems included autoimmune haemolytic anaemia, massive splenomegaly and ITP. At the age of 21 years, he underwent splenectomy. On genetic screening, he was heterozygous for c.785T4C (I262T) mutation in exon 9 of the TNFRSF 6 gene that encodes Fas (type Ia ALPS). After the age of 25 years, his main clinical problem was refractory recurrent ITP despite treatment with steroids, mycophenolate mofetil, azathioprine, intravenous immunoglobulins (IVIG), vincristine and rituximab. His HLAidentical sister was 28 years of age and asymptomatic, despite being heterozygous for the same Fas mutation as the patient. The transplant conditioning consisted of Campath-1 H, fludarabine and melphalan. 6 Cyclosporin was given for GVHD prophylaxis.
The early post-transplant period was only complicated by infections, including CMV reactivation and a respiratory infection, without acute GVHD. Neutrophil engraftment (40.5 Â 10 9 /l) occurred on day þ 11 and platelet engraftment (420 Â 10 9 /l and 450 Â 10 9 /l) on day þ 10. Cyclosporin was gradually tailed off and discontinued at 5 months post-transplant; however, this was associated with recurrence of his thrombocytopenia. A new bone marrow biopsy revealed numerous megakaryocytes, a finding consistent with peripheral platelet destruction. Specific anti-platelet antibodies tests in the monoclonal antibody immobilization of platelet antigen (MAIPA) assay revealed the presence of IgG and IgM autoantibodies against glycoprotein IIbIIIa (GPIIbIIIa). In the pretransplant sample, autoantibodies against GPIIbIIIa were detected with both PAB-1-and RFGP56-capture antibodies. When the patient relapsed, autoantibodies were demonstrated only with PAB-1, indicating that the footprint of the post-transplant antibody overlapped with RFGP56. It is likely that the transplant induced the selection of this particular clone from the polyclonal response that was present before transplant. The donor pre-transplant serum was negative for antiplatelet antibodies. Chimerism analysis performed by FISH using Xand Y-chromosome probes revealed mixed cell chimera of the T-cell (82% donor) and B-cell fraction (95% donor).
Initially he was treated with rituximab and it was decided that escalating doses of DLI would promote full-donor chimerism and eliminate any residual autoreactive clones producing anti-platelet antibodies.
Six months after the transplant, three escalating doses of DLI were given at three monthly intervals consisting of 1 Â 10 6 , 1 Â 10 7 and 3.3 Â 10 7 T-cells/kg, respectively. The platelet count did not respond to the first two DLIs, and mixed T-cell chimerism persisted. The patient required IVIG and a short course of steroids, as shown in Figure 1 , which only transiently increased his platelet count. Repeated MAIPA assay at this stage showed autoantibodies against GPIIbIIIa with both PAB-1 and RFGP56, similar to the pre-transplant profile.
Two months after the third DLI, the patient developed oral and skin GVHD, which coincided with resolution of the thrombocytopenia. The platelet count had already normalized by the time the patient required systemic oral steroids and cyclosporine for the treatment of GVHD. The anti-platelet antibodies were no longer detectable by MAIPA and chimerism was the 100% donor in all lineages. The patient remains on cyclosporin 15 months after third DLI. His platelet count remains normal.
So far, only two other patients with ALPS treated with SCT have been reported. One of them was a 4-year-old child with severe ALPS and oligoclonal T-cell lymphoproliferation resembling a high-grade lymphoma; he received a T-cell replete HLA-A-mismatched unrelated transplant and remained in remission with full-donor chimerism for 40 months. 7 The other was a child with homozygous Fas deletion and severe ALPS who received two sequential haploidentical myeloablative transplants from his parents after initial graft rejection. 8 Donor chimerism and response of the lymphoproliferation was finally achieved.
We report the first adult patient with ALPS successfully treated with an RIC transplant, and DLI. Engraftment was feasible, but thrombocytopenia relapsed as a result of mixed chimerism and residual recipient autoreactive B-cell clones. Escalated doses of DLIs promoted full-donor chimerism eliminating autoreactive clones, which were substituted by donor-derived B cells. Disappearance of the thrombocytopenia coincided with GVHD. The choice of a stem cell donor carrying the same mutation raises some interesting points. The 28-year-old donor carried the same Fas mutation as the patient, but never had any lymphoproliferation or autoimmunity. ALPS usually presents in childhood and variability in the clinical presentation and the penetrance of Fas gene mutations is well documented within affected families. In heterzygous individuals, various factors may determine clinical phenotype. A recent report suggests that HLA-B44 might play a protective role. 9 However, in this case both the patient and the sibling donor expressed HLA-B44.
In view of this case, RIC transplantation is a feasible treatment option for patients with ALPS and refractory autoimmune disease. RIC regimens minimize toxicity and DLIs, if required, can promote full donor chimerism and exhibit a graft versus autoimmunity effect. 
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